Receive our newsletter – data, insights and analysis delivered to you
June 15, 2009

Euro Commission Approves Genzyme Kidney Drug Renvela

The European Commission has approved Genzyme's Renvela (sevelamer carbonate), a drug for the control of serum phosphorus in patients with chronic kidney disease (CKD). Renvela is a new version of Renagel (sevelamer hydrochloride), a calcium-free, metal-free, non-absorbed phosphate binder,

By cms admin

The European Commission has approved Genzyme’s Renvela (sevelamer carbonate), a drug for the control of serum phosphorus in patients with chronic kidney disease (CKD).

Renvela is a new version of Renagel (sevelamer hydrochloride), a calcium-free, metal-free, non-absorbed phosphate binder, which has the added benefit of a carbonate buffer.

Professor of medicine and clinical nephrologist Markus Ketteler said that hyperphosphataemia was a significant risk factor for cardiovascular disease in patients with CKD.

“Renvela is an important addition to the therapeutic options available to nephrologists, and gives them the opportunity to treat hyperphosphataemia earlier,” Ketteler said.

Genzyme has been working with regulatory officials worldwide to secure additional approvals for Renvela, which has also recently been launched in India for CKD patients on dialysis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU